By Canadian Press

Medicago reports promising early Phase 1 test results of possible COVID-19 vaccine

Nov 10, 2020 | 6:53 AM

QUEBEC — Medicago says it has received promising early test results for its plant-derived vaccine for COVID-19.

The Quebec City-based company says interim results of a Phase 1 clinical trial found that 100 per cent of subjects developed a promising antibody response after two doses of its COVID-19 vaccine candidate.

Medicago says the side effects were generally mild to moderate and short in duration.

The Phase 1 clinical trial was a randomized, partially blinded study of 180 healthy people.

Based on the Phase 1 data, Medicago plans to proceed with a Phase 2/3 clinical trial for its COVID-19 vaccine candidate, subject to regulatory approval.

new mayor

Spring Mayoral by-election called in Ladysmith

12h ago

holiday check stops

Nanaimo motorists shine during province-wide crackdown

15h ago

targeted job action

Striking Nanaimo postal workers disrupt Purolator operations

19h ago

The federal government has signed deal with Medicago to secure the rights to buy 76 million doses of its vaccine. Medicago will also receive $173 million in funding from Ottawa for its vaccine research and development and for the  construction of its Quebec City manufacturing facility.

This report by The Canadian Press was first published Nov. 10, 2020.

The Canadian Press

Note to readers: This is a corrected story. An earlier version incorrectly described the federal government funding.